Introduction: Etomidate is a hypnotic drug widely used as an intravenous anesthetic induction agent. The incidence of etomidate-induced myoclonus has been reported as much as 50-80% after induction making it an undesirable drug for induction.
Objective: Our aim is to use a priming dose of atracurium to suppress etomidate-induced myoclonus during induction of anesthesia.
Methods: In a double-blinded clinical trial 80 patients were randomly given either atracurium (20% of ED95 × kg) or saline as a priming agent. Then, induction of anesthesia was performed using 0.4 mg/kg etomidate. Age, weight, body mass index, bispectral index (BIS) monitor, and duration and grade of myoclonus were recorded.
Results: The demographic characteristics, age, body mass index, BIS score, and weight were not significantly different between the atracurium (ATRA) priming group and control groups. The binomial regression model showed that BMI was an independent predictor variable for myoclonus (OR: 2.1, CI 95%: 1.7-7.5, p = 0.032). In this model, adjusted odds ratios (OR) of myoclonus (multivariate logistic regression analysis) in the control group was 6.6 (95% CI: 1.5-9.7, p = 0.013).
Conclusion: Low-dose atracurium priming could effectively suppress etomidate-induced myoclonus.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.aat.2013.12.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of Pretreatment with a Small Dose of Esketamine on Myoclonus Induced by Etomidate: A Randomized Controlled Trial.
Drug Des Devel Ther
December 2024
Department of Anesthesiology, Suzhou Hospital Affiliated to Nanjing Medical University, Suzhou, People's Republic of China.
Background: Etomidate has been observed to precipitate myoclonus in patients undergoing induction of general anaesthesia. This study was designed to investigate the effect of pretreatment with a small dose of esketamine on the incidence of myoclonus induced by etomidate.
Methods: One hundred adult patients, who were scheduled to undergo selective operations with general anesthesia, were randomly divided into two groups, with one group receiving esketamine (Group E) and the other receiving normal saline (Group C).
Pretreatment with Esketamine Reduces Etomidate-Induced Myoclonus During the Induction of Anesthesia: A Randomized Controlled Trial.
Ther Clin Risk Manag
December 2024
Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China.
Background: Myoclonus is a common problem during induction of anesthesia with etomidate. A variety of agents, including opioids and lidocaine, reduced the incidence of myoclonus. However, there is no reported literature evaluating the effect of esketamine pretreatment on etomidate-induced myoclonus.
View Article and Find Full Text PDFDexamethasone alleviates etomidate-induced myoclonus by reversing the inhibition of excitatory amino acid transporters.
Front Neurosci
June 2024
Department of Anesthesiology, Sichuan Integrative Medicine Hospital, Chengdu, China.
Background: Etomidate can induce myoclonus with an incidence of 50 ~ 85% during anesthesia induction. Dexamethasone, as a long-acting synthetic glucocorticoid, has neuroprotective effects. However, the effects of dexamethasone on the etomidate-induced myoclonus remain uncertain.
View Article and Find Full Text PDFComparative assessment of dexmedetomidine and butorphanol for attenuation of etomidate-induced myoclonus: A double-blind, randomised controlled study.
Indian J Anaesth
September 2023
Department of Anaesthesiology and Critical Care, University College of Medical Sciences and GTB Hospital, Delhi, India.
Background And Aims: Etomidate is a popular induction agent, but its use is associated with myoclonus in 50%-80% of non-premedicated patients. This study aims to compare dexmedetomidine and butorphanol for their relative efficacy in preventing etomidate-induced myoclonus.
Methods: This randomised study was conducted after obtaining institutional ethical committee clearance and written informed consent from sixty American Society of Anesthesiologists (ASA) I or II consenting patients between 18 and 60 years of age of either sex who had been scheduled for elective surgeries under general anaesthesia.
Low-dose nalmefene pretreatment reduces etomidate-induced myoclonus: A randomized, double-blind controlled trial.
Medicine (Baltimore)
September 2023
Department of Clinical Medicine, Medical School of Nantong University, Nantong, Jiangsu, China.
Article Synopsis
- This study evaluated how well nalmefene and fentanyl work to reduce myoclonus (muscle spasms) caused by etomidate during anesthesia.
- It involved 150 patients who received either nalmefene, fentanyl, or a placebo, and measured myoclonus severity and incidence along with other side effects.
- The results showed nalmefene significantly reduced both the frequency and severity of myoclonus compared to fentanyl and the placebo, with no major differences in heart rate or blood pressure among the groups.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!